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Host immune system is designed (or evolved) to fight against different pathogens. Many 
viruses infect the immune cells for the propagation of new progenies, thus the infection may 
modulate the host immune homeostasis. It has been more than 45 years since the discovery 
of Epstein–Barr virus (EBV) from a Burkitt’s lymphoma derived cell line. The ability of EBV to 
transform primary B cells in vitro leads to the suggestion for its oncogenic potential. However, 
except the clear understanding of the role of EBV in post-transplantation lymphoproliferative 
disease, it remains ambiguous why such a ubiquitous virus causes malignant diseases only 
in a very small subset of individuals. Possible explanation is that EBV may cooperate with 
other environmental and host genetic factors and lead to the development of EBV associated 
neoplastic diseases. In addition to infecting B cells, recent studies revealed that EBV may impact 
host immune system more broadly than previously thought, for example the development of 
regulatory NKT subsets. Instead of an intensive review, this article aims to provide a linkage to 
recent advances on the interplay between EBV and host immune system and to inspire further 
studies on EBV related diseases, especially autoimmune diseases.
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receptor-associated factor (TRAF)-binding domains and interacts 
with multiple members, in a B cell activation molecule CD40 
mimicking pattern that can activate STAT, JNK, and NF-κB path-
ways and lead to B cell survival and growth. On the other hand, 
LMP2A contains immunoreceptor tyrosine-based activation 
motifs (ITAMs) and associates with Lyn kinase, and LMP2A can 
then replace the survival signal provided by B cell receptor (BCR; 
Caldwell et al., 1998). Overall, the EBV-infected naïve B cell blasts 
proliferate in a way that resembles the antigen-activated blasts 
(Thorley-Lawson and Mann, 1985). However, different from 
terminally differentiated plasma cells that eventually undergo 
apoptosis, these EBV positive cells follow the path of B cell dif-
ferentiation into memory B cells through migration into germi-
nal center (GC; Thorley-Lawson, 2001). Four different types of 
latency programs were defined according to the expression profile 
of EBV latent genes. These memory cells do not express EBNA-1 or 
other latent proteins (referred as latency 0) under normal condi-
tion, but only express EBNA-1 when cells are dividing (Hochberg 
et al., 2004). In vitro, the EBV transformed lymphoblastoid cell 
line (LCL) with all eight viral latent proteins, EBV encoded small 
RNA (EBERs), and BamHI A transcripts can be continuously 
propagated. EBNA-1, EBNA-2, EBNA-3A, EBNA-LP, and LMP1 
are required for this transformation process (Kutok and Wang, 
2006). Because of the strong immunogenicity of EBV latent pro-
teins, the LCL-like viral gene expression pattern (Type III latency), 
can only be observed in immunocompromised patients in vivo. 
Alternatively, EBV positive Burkitt’s lymphoma (BL) cells express 
only EBNA-1 and EBV encoded RNAs (Type I latency), whereas 
cells with Type II latency expressing also LMP1 and LMP2 are 
observed in Hodgkin’s disease (HD).
EpstEin–Barr virus
Epstein–Barr virus (EBV) is a gamma-herpesvirus with a 172-kb 
DNA genome, which infects more than 90% of world population. 
EBV is a successful virus that utilizes normal B cell biology to infect, 
persist, and replicate in B cells (Thorley-Lawson, 2001; Thorley-
Lawson and Gross, 2004). EBV predominantly infects resting B 
lymphocytes through complement receptor 2 (CD21) in vitro (for 
a review of EBV biology, Young and Rickinson, 2004). Primary 
infection of EBV may cause short term proliferation of B cells in 
human hosts. The infection is usually self-limited and controlled 
by the strongly elevated T cell immune response. If the infection 
occurs in adolescence or adulthood, up to 50% T cells in the host 
can be specific to the virus, which may cause the clinical symptom 
of infectious mononucleosis (IM). EBV then persists latently in the 
host within long-life memory B cells.
During latency, up to eight EBV encoded proteins and several 
non-coding RNAs are expressed. These include two EBV encoded 
small RNAs (EBER1 and EBER2), nuclear antigens, and membrane 
proteins. EBV nuclear antigen 1 (EBNA-1) binds to the latent viral 
DNA replication origin and maintains the viral genome in the 
EBV positive cells after cell division (Yates et al., 1985). EBNA-2 
interacts with a DNA binding protein CBF1 through mimicking 
Notch signaling pathway, blocks differentiation, and allows cell 
proliferation (Ling et al., 1994). Two EBV latent membrane pro-
teins (LMPs) adopt the signaling pathways involved in B cell acti-
vation and differentiation to sustain the long-life of EBV positive 
cells. Both LMP1 and LMP2A are multiple membrane-spanning 
proteins that function as constitutive active receptors independent 
of ligand binding (Gires et al., 1997). On one hand, the carboxyl 
terminus of LMP1 contains  consensus tumor- necrosis-factor-
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1994). Under normal situation, antigen-activated B cells go to 
GC for somatic hypermutation to generate high affinity BCRs, 
and those cells with unfavorable mutations will be eliminated 
through Fas-mediated apoptosis. The current scenario for HL is 
that the expression of EBV genes may prevent the apoptosis of 
cells with certain mutations and promote them into HRS cells 
(Kapatai and Murray, 2007).
EBv and nKt cEll dEvElopmEnt
It has been a longtime question why EBV only causes these malig-
nant diseases within a small portion of infected population. Recent 
studies further indicated that EBV infection may regulate CD8+ 
NKT development in the host; and the failure of CD8+ NKT con-
version may contribute to disease development in some cases 
(He et al., 2010). NKT cells are unconventional T cells that are 
CD1d-restricted, lipid antigen-reactive, immune regulatory T lym-
phocytes. NKT cells can produce a broad range of cytokines upon 
antigen stimulation within minutes to hours. Different subsets of 
NKT are involved in regulating cell-mediated immunity to various 
infectious organisms, cancer, allergy, and autoimmune diseases. It 
is still unclear why such a small subset of T cells [T cell receptor 
(TCR)-α Vα14-Jα18] can have such broad influence. Most notably, 
NKT cell numbers vary substantially between individuals (from 
undetectable to over 3% of blood lymphocytes). This may be either 
the result of differences in intrathymic development, migration 
efficiency or the maintenance, or expansion in peripheral blood 
(for a review, Godfrey et al., 2010). Generally speaking, type I NKT 
cells can mediate strong antitumor responses on α-GalCer-induced 
IFN-γ and drive T cells into Th1-bias. Type II NKT cells suppress 
tumor immunity through IL-13 secretion (Berzofsky and Terabe, 
2008). It is therefore attractive to study the NKT population vari-
ation in different diseases and ask how the NKT population could 
be manipulated.
A recent study revealed that the frequencies of regulatory CD8+ 
NKT, but not CD4+ NKT cells, in EBV associated HL and NPC 
patients are much lower than that in healthy EBV carriers (Yuling 
et al., 2009). In the human-thymus-sever combined immunode-
ficient (hu-thy-SCID) chimera mouse model, the authors further 
demonstrated that EBV promotes the generation of IFN-γ-biased 
EBV specific CD8+ NKT cells, which can suppress tumorigenesis 
by EBV associated malignancies in vivo (Xiao et al., 2009; Yuling 
et al., 2009). To further illustrate the interplay between EBV and 
NKT development, the same group demonstrated that the aver-
age frequency of total and CD8+ NKT cells in peripheral blood 
mononuclear cells (PBMCs) of healthy EBV latent individuals is 
significantly higher than that in patients with acute EBV IM or 
HL, and in EBV-negative normal control subjects. EBV challenge 
induced a population of NKT precursors develops and differenti-
ates into mature CD8+ NKT cells in the thymus and liver of human-
thymus/liver-SCID chimera mouse model. These CD8+ NKT cells 
produce more perforin and are CD8αα positive, similar to that 
detected on CD8+ NKT cells in PBMCs from healthy latent EBV-
infected subjects and IM patients at 1 year post-onset. The authors 
proposed that thymic EBV-infected dendritic cells and IL-7 may 
regulate the CD8+ NKT development process. It clearly demon-
strated that EBV can induce differential CD4 versus CD8 lineage 
commitment, in addition to known classical endogenous elements 
EBv and its associatEd malignant disEasEs
The above mentioned information indicates that after primary 
infection, a subset of EBV positive B cells survive and emerge 
into the memory compartment. These cells can go for limited 
 expansion or extrafollicular proliferation and sustain in the host 
for a longtime. The virus can be reactivated periodically and infect 
new hosts through shedding in saliva. In addition to B cell, EBV 
also infects epithelial cells and maybe some T cells. EBV is also 
highly associated with several neoplastic diseases, such as endemic 
BL, T cell lymphoma, nasopharyngeal carcinoma (NPC), HD, and 
immunoblastic lymphomas in immunocompromised patients 
(Young and Rickinson, 2004). Viral genomes or subsets of viral 
gene products can be detected in the tumor tissues, and antibody 
levels are usually elevated in patients’ sera. Though not fully illus-
trated, recent knowledge provides some hints to the EBV associated 
disease mechanisms.
The EBV associated BL (endemic BL in tropic Africa) demon-
strates that the complex interaction of EBV with B cells predisposes 
the development of BL (for reviews, Brady et al., 2008; Thorley-
Lawson and Allday, 2008). Malaria infection in endemic region is 
considered as another co-factor for the development of BL. EBV-
negative BL also occurred in other area, and myc-translocation 
to Ig locus is the most critical feature observed in both sporadic 
and endemic BLs. The translocation is highly dependent on the 
enzyme activity of AID (activation-induced cytidine deaminase; 
Muramatsu et al., 2000; Pasqualucci et al., 2008). AID is highly 
expressed in GC to provide the class switch and hypermutation of Ig 
variable region. After translocation, the activated myc on one hand 
can lead to cell growth and proliferation, but myc also leads to p53 
and BIM dependent apoptosis. Effects of EBV proteins may prevent 
B cells from myc induced apoptosis, thus sustain the survival of 
these memory B cells. The malaria infection may represent a chronic 
antigenic stimulation with repeated opportunistic infections that 
can promote more EBV-infected cells to become memory cells. 
It is still not clear whether chronic B cell antigen stimulation can 
link to the prolonged or atypical expression of AID, and lead to 
the higher frequency of myc-translocation (Thorley-Lawson and 
Allday, 2008).
Hodgkin’s lymphoma (HL) is characterized by the presence 
of a minority of malignant Hodgkin/Reed Sternberg (HRS) 
cells among a background of non-neoplastic B and T cells 
(For a review, Kapatai and Murray, 2007). A complex cytokine 
cross-talk among HRS cells and neighboring cells may provide 
proliferative and anti-apoptotic signals for tumor cell growth. 
According to the WHO classification, HL can be divided into 
two major types: classical and nodular lymphocyte predominant 
HL (Harris et al., 1999). EBV is associated with only subsets 
of classical HL. Nevertheless, EBV positive and negative HLs 
share similar morphological patterns, while different signaling 
pathways are involved in the pathogenesis. Most EBV positive 
HLs belong to the mixed cellularity subtype in classical HL. EBV 
positive HRS cells display type II latency gene expression profile 
with EBERs, EBNA-1, LMP1 and LMP2, and BamHI A rightward 
transcripts (BARTs). The lack of expression of functional surface 
immunoglobulin is the hall mark of classical HL. But because 
of the clonally rearranged immunoglobulin genes identified in 
HRS cell, the B cell origin of HL is confirmed (Kuppers et al., 
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T cell  cytotoxicity toward EBV positive plasma cells (Serafini 
et al., 2007). Further study of the intrathecal B cells indicated 
that these cells are CD27+ antigen-experienced cells and with 
the co-expression of LMP1 and 2A. Moreover, LMP2A positive 
cells also express B cell-activating factor of the tumor-necrosis 
factor family (BAFF), suggesting these cells are responsible for 
persistent intrathecal synthesis of oligoclonal antibodies. The 
EBV positive cell pattern is very similar to the ectopic follicles 
observed in the tonsil of healthy EBV carriers. The disease model 
of MS was proposed by the authors that through the prolifera-
tive, anti-apoptotic, and B cell activation signals provided by EBV 
latent proteins, EBV may promote the intracerebral expansion 
and maturation of B cells and form ectopic lymphoid follicles. It 
also explains that the oligoclonal IgG in the CSF and brain tis-
sue is synthesized persistently by EBV positive B cells (Serafini 
et al., 2010). There are still remaining questions. Why are the EBV 
positive B cells homing to brain? Are these EBV positive cells the 
cause or the consequence of MS?
Other possibilities for the contribution of EBV in MS are also 
proposed by other groups. The idea is that virus positive cells may be 
few, but these cells may induce enough pro-inflammatory cytokine 
production and lead to the development of disease. For example, 
EBV was demonstrated to infect primary human brain microves-
sel endothelial cells in vitro (Casiraghi et al., 2011). The infection 
also leads to increased production of several pro-inflammatory 
mediators, such as CCL-5 and ICAM-1, which may promote adhe-
sion of leukocytes to the endothelium. It is likely that the entry 
of autoreactive T cells may follow a breach of the blood–brain 
barrier (BBB) and lead to CNS lesions in MS. It explains why viral 
and myelin-specific lymphocytes and macrophages infiltrate into 
MS brains, and interferon-beta treatment may prevent MS relapse 
through blocking virus replication and subsequent production of 
cytokines (Casiraghi et al., 2011). Alternatively, another recent study 
focused on the development of CD8+ cytotoxic T cells observed 
in MS patients (Ji et al., 2010). The authors used a major histo-
compatibility complex (MHC) class I-restricted TCR transgenic 
model that generates CD8+ myelin basic protein (MBP) specific 
T cells to study the break of CD8+ T cell tolerance and induction 
of CNS autoimmunity. The results indicate that viral  infection 
triggers the activation of CD8+ T cells bearing dual TCRs in the 
experimental animals, suggesting these T cells may contribute 
to CNS autoimmune diseases (Ji et al., 2010; Ransohoff, 2010). 
Indeed, dual-receptor TCRs are present in humans and proposed 
to enhance antiviral defense. The second receptor could be against 
myelin in a small subset of individuals, which may be associated 
with specific MHC II subtypes. It is possible that reinfection or 
reactivation of the specific virus may activate the T cell antiviral 
memory and also the anti-myelin activity (Ransohoff, 2010). The 
question then is why infection of EBV, but not other viruses, links 
to the development of MS.
We may then think again the stimulatory effect of EBV on NKT 
development, regarding the viral modulation on immune system 
(He et al., 2010). It was previously known that the infection of HIV 
or HTLV-1 may result in a decrease in NKT cells (Lin et al., 2005; 
Azakami et al., 2009). It thus indicates that various viral infections 
may have different impacts on the development of host immune 
response, and EBV may be a very unique virus. From an evolution 
(He et al., 2010). Thus the distinctive subsets of CD4+ and CD8+ 
NKT cells in EBV-infected individuals may differentially modify 
the pathogenesis of EBV. Alternatively, it may be possible that the 
biased NKT will affect the specific individual’s response to later 
infections or malignant diseases.
EBv and autoimmunE disEasEs
Keeping the above observation in mind, we may check possible 
mechanisms involved in EBV associated autoimmune diseases, such 
as systemic lupus erythematosus (SLE) and rheumatoid arthritis 
(RA; for a review, Toussirot and Roudier, 2008). Both SLE and 
RA are complex disorders with a genetic background, as suggested 
by familial cases. Patients of both diseases have higher titers of 
anti-EBV antibodies, impaired T cell responses to EBV antigens 
and higher viral load in PBMCs (James et al., 2001; Poole et al., 
2006). EBV DNA or RNA was detected in the target organs of 
RA. Molecular mimicry between EBV and lupus autoantigens was 
reported. Antibodies against cross-reactive epitopes containing 
glycine–alanine rich sequences and cellular nuclear antigens were 
identified (Vaughan et al., 1995). A proposed disease mechanism 
is the interplay between genetic predisposition and EBV infection 
leads to the development of cross reacting autoantibodies, and later 
the non-cross-reactive antibodies against autoepitopes (Toussirot 
and Roudier, 2008).
In addition to SLE and RA, multiple sclerosis (MS) is another 
EBV associated chronic inflammatory disease with repetitive dam-
ages of myelin sheet in the central nervous system (CNS). MS is 
a disease that also has been linked to genetic and environmental 
factors (for a review, Compston and Coles, 2008). Based on the 
geographic distribution, MS was proposed to be a rare disease that 
caused by a common infection. The most promising data suggest-
ing EBV as the viral factor is that the risk of MS is 20 times higher 
among people who have contracted IM, as compared with seron-
egative individuals (Ascherio and Munger, 2007). In a large scale 
follow-up study for MS development in US military, the risk of 
MS increased with elevated levels of serum antibodies to EBNA 
complex and less strongly to VCA IgG. Some of the serum anti-
body levels were elevated even 5 years before disease development 
(Levin et al., 2005; Compston and Coles, 2008). Detection of EBV 
specific antibodies in MS patients also showed a highly correla-
tion in other studies. However because EBV is highly prevalent in 
healthy population, it has been a long-term debate on the role of 
EBV as the etiology agent of MS. The detection of EBV DNA or 
viral proteins by different groups then gave controversial results, 
which may be due to different samples included or the sensitivities 
of assays employed (Lunemann and Munz, 2009).
Recent detection of EBV markers in the postmortem brain 
tissue from patients with secondary progressive phase of MS thus 
provide a clue for the pathogenic contribution of EBV to MS 
patients. The breakthrough study by Serafini et al. (2007) dem-
onstrated that almost 100% of the early onset MS cases with the 
secondary progressive phase contain dysregulated EBV infected 
plasma cells in MS brains. LMPs were regularly detected in MS 
brains, whereas viral lytic proteins were only detected in ectopic 
B cell follicles and acute lesions. Notably, activated CD8+ T cells 
with membrane associated perforin staining were observed at 
sites of major accumulation of EBV-infected cells, suggesting 
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point of view, it is plausible that EBV may serve certain roles to 
help immune system development in most population. The EBV 
associated diseases may be rare events resulting from host genetic 
variations, which let the host immune system be modified by 
EBV in a bias manner. The disease statuses may develop upon the 
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